Main menu button

Elicera Therapeutics AB

Elicera Therapeutics develops new cell therapy treatments based on the enhancement of validated techniques. Major focus is on the CAR-T area where the market is expected to multiply in the coming years. Elicera intends to address rare cancers such as lymphoma and brain cancer, which opens for potentially faster clinical development than the average drug project.

Initial coverage: December 13, 2021
Industry: Biotech
List: Nasdaq OMX, First North
Ticker: ELIC:SS
Niklas Elmhammer
Niklas Elmhammer LinkedIn
Senior Equity Analyst

Other Researches